A recent report on CAR-T Therapy Market provides a detailed analysis of the industry size, revenue forecasts and geographical landscape pertaining to this business space. Additionally, the report highlights primary obstacles and the latest growth trends accepted by key players that form a part of the competitive spectrum of this business.
CAR-T Therapy Market Size
Global CAR-T Therapy Market is valued at USD 708.5 Million in 2020 and expected to reach USD 4791.1 Million by 2027 with a CAGR of 31.4% over the forecast period.
Get Sample Copy of This Premium Report @ https://brandessenceresearch.com/requestSample/PostId/1553
Scope of CAR-T Therapy Market Report:
Chimeric antigen receptor-T (CAR-T) cell therapy is an extremely encouraging therapy for cancer patients. CAR-T is a kind of immunotherapy where doctors collect immune cells from a patient, change cells in a research center and give cells the ability to easily identify and destroy cancer cells and mix it back into the patient. This arising therapy is possibly the greatest forward leap since the introduction of chemotherapy. The implanted cells get increased and stay in the body as living drugs. CAR-T cells are genetically designed cell receptors that are attached to the T-cells of the cancer patients and mixed through the circulation system that initiates the immune system to destroy cancer causing cells in the body. Also, CAR T-cell therapy is confirmed for patients with decline or inflexible acute lymphoblastic leukemia up to age 25. There are additionally numerous clinical trials of CAR T-cell therapy for different sorts of blood cancer and strong tumors.
COVID-19 pandemic has made huge interruption to the CAR-T therapy industry. Currently, the COVID-19 pandemic is influencing the consistency of essential routine medical care services and systems, including chimeric antigen receptor T-cell (CAR-T) therapy, a daily existence saving alternative for patients with relapsed/refractory hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. And, due to various restrictions during Covid-19 many existing trials and read outs have been delayed despite and new trials completely suspended. Thus, Covid-19 situation has shown a decline impact on the growth of Global CAR-T Therapy Market.
Global CAR-T therapy market is segmented on the basis of targeted antigen, application, end-user and region & country level. Based upon targeted antigen, CAR-T therapies market is classified into CD 19,CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso and EGFRvlll. Based upon application, the market is divided into acute lymphoblastic leukemia, diffuse large b-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma and others. Based upon end-user, CAR-T therapies market is classified into hospitals and cancer treatment centers.
Global CAR-T Therapy Market Segmentation:
By Targeted Antigen:
- CD 19
- CD 20
- Acute Lymphoblastic Leukemia
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Cancer Treatment Centers
The regions covered in this Global CAR-T Therapy Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market of global CAR-T therapies is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.
Request for Methodology @ https://brandessenceresearch.com/requestMethodology/PostId/1553
CAR-T Therapy Companies
Some major key players for Global CAR-T Therapy Market report cover prominent players are
- Pfizer Inc.
- Novartis International AG
- Noile-Immune Biotech Inc.
- Merck KGaA
- Gilead Sciences Inc.
- Gracell Biotechnology Ltd
- Aeon Therapeutics
- Sangamo Therapeutics Inc.
- Johnson & Johnson
- Amgen Inc.
- Celyad Oncology
- Nanjing Legend Biotechnology Co. Ltd.
- Intellia Therapeutics
- Celgene Corp. (acquired by Bristol-Myers Squibb)
- Caribou Biosciences Inc.
- Bluebird Bio Inc.
- Bellicum Pharmaceuticals Inc.
CAR-T Therapy News
Gracell Biotechnologies Announced Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL
March 31st, 2021; Gracell Biotechnologies Inc. had announced that first enrolled patient in their vital Phase 1/2 clinical investigation of GC007g, an allogeneic donor-derived against CD19 chimeric antigen receptor (CAR) – T cell treatment for the treatment of B-cell acute lymphoblastic leukemia (B-ALL). B-ALL, a main type of acute lymphoblastic leukemia (ALL), is one of the most common forms of cancer in children between the ages of two and five and adults over the age of 50. GC007g is an allogeneic HLA (human leukocyte antigen) – coordinated with benefactor derived CAR-T treatment.
Rising Prevalence of Cancer, Collaboration of Biotech and Pharma Companies, Increasing Funding by Government, Development of Latest and Effective Therapies to Cure Diseases are Driving the Market Growth
The major factor driving the growth of global CAR-T therapy market is increasing prevalence of cancer. As per the World Health Organization (WHO), cancer is second major causes for mortality around the world, representing an expected 10 million deaths every year. In 2018, 18.1 million individuals around the globe had cancer, and 9.6 million died from the diseases. In addition, growing number of partnerships between biotech and pharma companies are also fostering growth of the global CAR-T therapy market. As per a news published, in February 2018, Gilead Sciences Inc. joined forces with Sangamo Therapeutics Inc. for its gene-editing innovation to produce cancer treatment and it is assessed that the arrangement was worth USD 3 billion. Furthermore, rising development of latest and effective therapies to cure diseases is also supplementing the GLOBAL CAR-T therapy market. According to a news published on July 24th, 2020; FDA approved the third chimeric antigen receptor (CAR) T-cell therapy, this time giving a green light for Kite Pharma’s brexucabtagene autoleucel, the principal cell-based gene treatment to treat relapsed or headstrong mantle cell lymphoma (MCL).
However, high costs associated with the CAR-T therapy and difficulties associated with the CAR-T cell process may hamper the market growth. In spite of that, implementation of actions with highly developed technologies and innovative treatment procedures can offer more opportunities for the further growth of the market.
Complete Report Details @ https://brandessenceresearch.com/healthcare/t-cell-therapy-market
North America is Expected to Dominate the Global CAR-T Therapy Market
North America is expected to dominate the global CAR-T therapy market owing to the rising number of cancer patients, presence of key players and landmark approvals of CAR T-Cell therapies by the U.S. FDA in this region. According to National Cancer Institute, in 2020, an expected 1,806,590 new cases of cancer was analyzed in the United States and 606,520 individuals expired from the diseases. For example, in November 2019, Precision BioSciences, Inc., a biotechnology organization produced a new generation allogeneic CAR-T treatment and is leading an ongoing trial of this treatment by making its most prominently the-shelf allogeneic CAR-T treatment competitor known as PBCAR0191. In U.S., the FDA approved a CAR-T cell treatment, supporting Kymriah in August 2017 and Yescarta in October 2017. Also, Novartis created Kymriah, a CAR-T treatment used to treat intense lymphoblastic leukemia. Kite Pharma created Yescarta, a CAR-T treatment to treat adult patients with particular sorts of enormous B-cell lymphoma .
Europe is projected to capture the significant revenue share in the global CAR-T therapy market due to growing research and development in the cancer therapies by governments in this region. For example; According to a news published in April 2018, both Kymriah and Yescarta secured agreement in Europe from the EMA. Kymriah is for the treatment of pediatric patients and youthful grown-ups with unmanageable or backslide (R/R) B cell antecedent acute lymphoblastic leukemia (ALL), however Yescarta is used for the therapy of grown-up patients with R/R enormous B cell lymphoma.
Asia Pacific is expected to witness a fastest growth in the global CAR-T therapy market due to the increasing count of cancer patients and growing number of collaboration between government and private organizations in the region. For example; ongoing epidemiological investigations done at the National Cancer Registry program in India reported that disease trouble in the nation is 2.5 to 3 million and around 700,000 – 900,000 number of new cases analyzed per year. Additionally, collaborations among different organizations and makers help in expanding the CAR-T therapies market in the future. For instance, EdiGene and Immunochina announced their partnership on R&D to create allogeneic CAR-T treatment for cancer in 2020. This partnership is further expected to create genome altering innovations to fast-track the drug invention and develop novel therapeutics for an expansive scope of illnesses.
Key Benefits for Global CAR-T Therapy Market Report:
- Global CAR-T Therapy Market report covers in-depth historical and forecast analysis.
- Global CAR-T Therapy Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.
- Global CAR-T Therapy Market report helps to identify opportunities in marketplace.
- Global CAR-T Therapy Market report covers extensive analysis of emerging trends and competitive landscape.
By Regional & Country Analysis: (North America, U.S., Canada, Europe, U.K., France, Germany, Italy,Asia Pacific, China, Japan, India, Southeast Asia, Latin America, Brazil, Mexico, Middle East and Africa, GCC, Africa, Rest of Middle East and Africa)
Table of Content
1. Chapter – Report Methodology
1.1. Research Process
1.2. Primary Research
1.3. Secondary Research
1.4. Market Size Estimates
1.5. Data Triangulation
1.6. Forecast Model
1.7. USP’s of Report
1.8. Report Description
2. Chapter – Global CAR-T Therapy Market Overview: Qualitative Analysis
2.1. Market Introduction
2.2. Executive Summary
2.3. Global CAR-T Therapy Market Classification
2.4. Market Drivers
2.5. Market Restraints
2.6. Market Opportunity
2.7. CAR-T Therapy Market: Trends
2.8. Porter’s Five Forces Analysis
2.9. Market Attractiveness Analysis
3. Chapter – Global CAR-T Therapy Market Overview: Quantitative Analysis
4. Chapter – Global CAR-T Therapy Market Analysis: Segmentation By Type
5. Chapter – Global CAR-T Therapy Market Analysis: Segmentation By Application
About Us: Brandessence Market Research and Consulting Pvt. ltd.
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Contact us at: +44-2038074155 or mail us at email@example.com